These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 15291979)
1. New molecular targets for treatment of lymphoma. Pro B; Younes A Curr Oncol Rep; 2004 Sep; 6(5):360-8. PubMed ID: 15291979 [TBL] [Abstract][Full Text] [Related]
2. The lymphomas: molecular pathways and novel therapeutic targets. Wedgwood A; Pro B; Younes A Curr Hematol Rep; 2005 Jul; 4(4):324-34. PubMed ID: 16009048 [TBL] [Abstract][Full Text] [Related]
3. New targets for lymphoma treatment. Johnson PW Ann Oncol; 2008 Jun; 19 Suppl 4():iv56-9. PubMed ID: 18519406 [No Abstract] [Full Text] [Related]
4. Treatment of mantle cell lymphoma: targeting the microenvironment. Drach J; Seidl S; Kaufmann H Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955 [TBL] [Abstract][Full Text] [Related]
6. Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma. Dutton A; Burns AT; Young LS; Murray PG Expert Rev Anticancer Ther; 2006 Jun; 6(6):911-9. PubMed ID: 16761935 [TBL] [Abstract][Full Text] [Related]
7. The role of the ubiquitin proteasome system in lymphoma. Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070 [TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition activates the transport and the ectodomain shedding of TNF-alpha receptors in human endothelial cells. Peiretti F; Canault M; Bernot D; Bonardo B; Deprez-Beauclair P; Juhan-Vague I; Nalbone G J Cell Sci; 2005 Mar; 118(Pt 5):1061-70. PubMed ID: 15731011 [TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of the proteasome in leukaemia. McCloskey SM; McMullin MF; Walker B; Irvine AE Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639 [TBL] [Abstract][Full Text] [Related]
10. New therapeutic targets and drugs in non-Hodgkin's lymphoma. Sawas A; Diefenbach C; O'Connor OA Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386 [TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Leonard JP; Furman RR; Coleman M Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600 [TBL] [Abstract][Full Text] [Related]
13. New oncology strategy: molecular targeting of cancer cells. Capriotti T Medsurg Nurs; 2004 Jun; 13(3):191-5. PubMed ID: 15219169 [No Abstract] [Full Text] [Related]
14. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. O'Connor OA J Clin Oncol; 2005 Sep; 23(26):6429-36. PubMed ID: 16155030 [TBL] [Abstract][Full Text] [Related]
15. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Klasa RJ Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174 [TBL] [Abstract][Full Text] [Related]
17. Current stumbling blocks in oncology drug development. Gimmi CD Ernst Schering Res Found Workshop; 2007; (59):135-49. PubMed ID: 17117720 [TBL] [Abstract][Full Text] [Related]
18. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622 [TBL] [Abstract][Full Text] [Related]
19. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas. Delmonte A; Ghielmini M; Sessa C Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Fanale MA; Younes A Drugs; 2007; 67(3):333-50. PubMed ID: 17335294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]